P/B
15,4
Exagen
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
$188.5M
Market Cap • 10/27/2026
2002
(24 years)
Founded
2019
(7 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
2,7
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,5
EPS
—
Market Cap
Market Cap
188,5M
EV
191,5M
EV/Revenue
2,7
EV/EBITDA
-17,8
EV/EBIT
-14,5
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-2%
Total Yield
-2%
Payout
0%
Retained Earnings
-321,4M
Profitability
Gross Margin
58,6%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
9,1%
Capex/Revenue
1,5%
Capex/D&A
44,7%
Capex/OCF
-16,8%
SBC/OCF
—
% PPE
16,4%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
8,7%
CAGR Op. Income 5Y
-5,8%
CAGR Net Income 5Y
-1,5%
CAGR EPS 5Y
-11,2%
CAGR OCF 5Y
-15,2%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
3,2
Quick Ratio
2,7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!